Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01576549 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2127399 in Rheumatoid Arthritis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01576549: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT01576549 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01576549, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will investigate how LY2127399 works in participants with rheumatoid arthritis (RA) who are not adequately responding to methotrexate. Participants will receive LY2127399 via an injection(s) under the skin at 4 week intervals for up to 52 weeks. Key study procedures include biopsies of the lining of an inflamed joint and blood tests to measure RA activity.
Primary Outcome
Primary and secondary analyses were not conducted given insufficient data due to termination of the trial.
Interventions
- DRUG LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Why NCT01576549 stopped before completion
NCT01576549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which LY2127399 is the first listed.
NCT01576549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01576549 about?
NCT01576549 is a clinical study titled "A Study of LY2127399 in Rheumatoid Arthritis". This study will investigate how LY2127399 works in participants with rheumatoid arthritis (RA) who are not adequately responding to methotrexate. Participants will receive LY2127399 via an injection(s) under the skin at 4 week intervals for up to 52 weeks. Key study procedures include biopsies of th...
What is the current status of trial NCT01576549?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-05. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01576549?
The interventions under investigation include: LY2127399 (DRUG).
Who is sponsoring clinical trial NCT01576549?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01576549's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia